ReviewHepatobiliary surgery and nutrition2022
Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition).
Open access · diamondAbstract readReview
In one paragraph
Review in Hepatobiliary surgery and nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 136 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
136citing papers in PubMed, 3 pooled it
25.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
136 citing papers in PubMed, 3 syntheses or guidelines pooled it, 193 citations in OpenAlex.
- Pathological and Perioperative Outcomes of Conversion Hepatectomy After Contemporary Combination Downstaging for Initially Unresectable Hepatocellular Carcinoma: A Systematic Review.Current oncology (Toronto, Ont.) · 2026Pooled it
- Taiwan liver cancer association management consensus guidelines for intermediate-stage hepatocellular carcinoma.Clinical and molecular hepatology · 2025Guideline
- Non-surgery strategy versus hepatectomy in hepatocellular carcinoma patients with complete response after conversion therapy: a meta-analysis.World journal of surgical oncology · 2024Pooled it
- Efficacy and safety of pembrolizumab, lenvatinib, and reduced-dose gemcitabine/oxaliplatin as initial treatment for advanced biliary tract cancer: a multicenter, single-arm, prospective, phase II study.Journal for immunotherapy of cancer · 2026Trial
- Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study.Signal transduction and targeted therapy · 2026Trial
- Trial
- The efficacy and safety of PD-1 inhibitors combined withFrontiers in medicine · 2025Trial
- Safety and efficacy of precision hepatectomy in the treatment of primary liver cancer.BMC surgery · 2023Trial
- Article
- Percutaneous Cryoablation Versus Microwave Ablation for Hepatocellular Carcinoma: Comparative Study of Safety and Oncologic Outcomes.Radiology. Imaging cancer · 2026Article
- Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006).Liver cancer · 2026Article
- Advances in Lipid Metabolism Reprogramming in Hepatocellular Carcinoma.Journal of clinical and translational hepatology · 2026Review
- Immunotherapy-Based Conversion to Curative-Intent Treatment in Hepatocellular Carcinoma: A Multidisciplinary Framework.Cancers · 2026Review
- Personalised decision-making in hepatocellular carcinoma: conceptual evolution over two decades.BJS open · 2026Review
- The role of liver stiffness measurement in predicting Long-term liver function after partial hepatectomy.Abdominal radiology (New York) · 2026Article
- Efficacy and safety of transarterial chemoembolization (TACE) with tislelizumab and tyrosine kinase inhibitors versus TACE for intermediate and advanced HCC.Journal of cancer research and clinical oncology · 2026Article
- Definition of Conversion Therapy and Neoadjuvant Therapy for Hepatocellular Carcinoma: A Consensus Guideline from the Japan Liver Cancer Association.Liver cancer · 2026Article
- Neoadjuvant or conversion therapy nullifies the prognostic impact of surgical margin width in hepatocellular carcinoma: a single-center retrospective study.BMC surgery · 2026Article
- Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002).Communications medicine · 2026Article
- Optimal duration of adjuvant targeted-immunotherapy in patients with initially unresectable hepatocellular carcinoma with portal vein tumor thrombus following successful conversion therapy.The oncologist · 2026Article
76 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
80 authors at 20 institutions in 1 country.
Hui-Chuan SunDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Jian ZhouDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Zheng WangDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Xiufeng LiuDepartment of Medical Oncology of PLA Cancer Center, Jinling Hospital, Nanjing, China.
Qing XieDepartment of Infectious Disease, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Weidong JiaDepartment of Liver Surgery, The First Affiliated Hospital of USTC, Hefei, China.
Ming ZhaoMinimally Invasive Interventional Division, Sun Yat-sen University Cancer Center, Guangzhou, China.
Xinyu BiDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Gong LiDepartment of Radiation Oncology, Beijing Tsinghua Changgung Hospital, Beijing, China.
Xueli BaiDepartment of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Yuan JiDepartment of Pathology, Fudan University Shanghai Cancer Centre, Shanghai, China.
Li XuDepartment of Liver Surgery, Sun Yat-sen University Cancer Centre, Guangzhou, China.
Xiao-Dong ZhuDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Dousheng BaiDepartment of Hepatobiliary Surgery, Clinical Medical College, Yangzhou University, Yangzhou, China.
Yajin ChenDepartment of Hepatobiliopancreatic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Yongjun ChenDivision of Hepatobiliary Surgery, Department of General Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Chaoliu DaiDepartment of Hepatobiliary and Splenic Surgery, Shengjing Hospital Affiliated to China Medical University, Shenyang, China.
Rongping GuoThe Department of Hepatobiliary Oncology of Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Wenzhi GuoDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Chunyi HaoKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Sarcoma Center, Peking University Cancer Hospital and Institute, Beijing, China.
Tao HuangDepartment of Hepatobiliary Surgery, Affiliated Tumour Hospital of Zhengzhou University, Zhengzhou, China.
Zhiyong HuangHepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Deyu LiDepartment of Hepato-Biliary Pancreatic Surgery, Henan Provincial People's Hospital, Zhengzhou, China.
Gang LiDepartment of Hepatobiliary Pancreatic Surgery, Changhai Hospital, Naval Military Medical University (Second Military Medical University), Shanghai, China.
Tao LiDepartment of general surgery, Qilu Hospital, Shandong University, Jinan, China.
Xiangcheng LiDepartment of Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Guangming LiCenter of General Surgery, Beijing YouAn Hospital, Capital Medical University, Beijing, China.
Xiao LiangDepartment of General Surgery, Zhejiang University, School of Medicine, Sir Run Run Shaw Hospital, Hangzhou, China.
Jingfeng LiuThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
Fubao LiuDivision of General Surgery, First Affiliated Hospital, Anhui Medical University, Hefei, China.
Shichun LuDepartment of Hepatobiliary Surgery, First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Zheng LuDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Bengbu Medical College Bengbu, China.
Weifu LvDepartment of Interventional Radiology, The Anhui Provincial Hospital, Hefei, China.
Yilei MaoDepartment of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC & Chinese Academy of Medical Sciences (CAMS), Beijing, China.
Guoliang ShaoDepartment of Intervention, Zhejiang Cancer Hospital, Hangzhou, China.
Yinghong ShiDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Tianqiang SongDepartment of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Guang TanDepartment of Hepatobiliary Surgery, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Yunqiang TangDepartment of Hepatic-Biliary Surgery, The Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, China.
Kaishan TaoDepartment of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Chidan WanDepartment of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Guangyi WangDepartment of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, China.
Lu WangLiver Surgery Department, Shanghai Cancer Center, Fudan University, Shanghai, China.
Shunxiang WangDepartment of Hepatobiliary Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Tianfu WenDepartment of Liver Surgery & Liver Transplantation Centre, West China Hospital of Sichuan University, Chengdu, China.
Baocai XingHepatopancreatobiliary Surgery Department I, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China.
Bangde XiangHepatobiliary Surgery Department, Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Key Laboratory for High-Incidence Tumor Prevention and Treatment, Ministry of Education, Guangxi Medical University Cancer Hospital, Nanning, China.
Sheng YanDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Dinghua YangUnit of Hepatobiliary Surgery, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Guowen YinDepartment of Intervention, Cancer Hospital of Jiangsu, Nanjing, China.
Tao YinDepartment of Hepatic & Biliary & Pancreatic Surgery, Hubei Cancer Hospital, Affiliated Hubei Cancer Hospital of Huazhong University of Science and Technology, Wuhan, China.
Zhenyu YinDepartment of Hepatobiliary Surgery, Zhongshan Hospital, Xiamen University, Fujian Provincial Key Laboratory of Chronic Liver Disease and Hepatocellular Carcinoma, Xiamen, China.
Zhengping YuDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Bixiang ZhangHepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jialin ZhangDepartment of Hepatobiliary Surgery, the First Hospital of China Medical University, Shenyang, China.
Shuijun ZhangKey Laboratory of Hepatobiliary and Pancreatic Surgery and Digestive Organ Transplantation of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Ti ZhangDepartment of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China.
Yamin ZhangDepartment of Hepatobiliary Surgery, Tianjin First Central Hospital, Tianjin, China.
Yubao ZhangDepartment of Hepatobiliary Pancreatic Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Aibin ZhangDepartment of Hepatobiliary Pancreatic Surgery, The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, China.
Haitao ZhaoDepartment of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ledu ZhouDepartment of Liver Surgery, Xiangya Hospital, Central South University, Changsha, China.
Wu ZhangDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Key Laboratory of Combined Multi-Organ Transplantation, Zhejiang Province, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Zhenyu ZhuHepatoliliary Surgery Center, 302 Hospital of PLA, Beijing, China.
Shukui QinQinhuai Medical Area, Eastern Theater General Hospital of PLA China, Nanjing, China.
Feng ShenDepartment of Hepatic Surgery IV, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Xiujun CaiDepartment of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, China.
Gaojun TengCenter of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.
Jianqiang CaiDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Minshan ChenDepartment of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
Qiang LiDepartment of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Lianxin LiuDepartment of Hepatobiliary Surgery, Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Weilin WangDepartment of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Tingbo LiangDepartment of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jiahong DongHepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Changping, Beijing, China.
Xiaoping ChenHepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xuehao WangHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation (Nanjing Medical University), Nanjing, China.
Shusen ZhengDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China.
Jia FanDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Alliance of Liver Cancer Conversion Therapy, Committee of Liver Cancer of the Chinese Anti-Cancer Association
Fudan University · CNNanjing General Hospital of Nanjing Military Command · CNSun Yat-sen University · CNRuijin Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNZhongshan Hospital · CNBeijing Tsinghua Chang Gung Hospital · CNShanghai Jiao Tong University · CNSun Yat-sen University Cancer Center · CNFudan University Shanghai Cancer Center · CNJiangsu Cancer Hospital · CNSecond Affiliated Hospital of Zhejiang University · CNZhejiang University · CNChanghai Hospital · CNGuangzhou Medical University · CNHuazhong University of Science and Technology · CNSecond Military Medical University · CNSouthern Medical University · CNTianjin Medical University · CNTongji Hospital · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in systemic and locoregional treatments for patients with unresectable or advanced hepatocellular carcinoma (HCC) have resulted in improved response rates. This has provided an opportunity for selected patients with initially unresectable HCC to achieve adequate tumor downstaging to undergo surgical resection, a 'conversion therapy' strategy. However, conversion therapy is a new approach to the treatment of HCC and its practice and treatment protocols are still being developed. Review the evidence for conversion therapy in HCC and develop consensus statements to guide clinical practice. Evidence review: Many research centers in China have accumulated significant experience implementing HCC conversion therapy. Preliminary findings and data have shown that conversion therapy represents an important strategy to maximize the survival of selected patients with intermediate stage to advanced HCC; however, there are still many urgent clinical and scientific challenges for this therapeutic strategy and its related fields. In order to summarize and learn from past experience and review current challenges, the Chinese Expert Consensus on Conversion Therapy for Hepatocellular Carcinoma (2021 Edition) was developed based on a review of preliminary experience and clinical data from Chinese and non-Chinese studies in this field and combined with recommendations for clinical practice. Sixteen consensus statements on the implementation of conversion therapy for HCC were developed. The statements generated in this review are based on a review of clinical evidence and real clinical experience and will help guide future progress in conversion therapy for patients with HCC.
Indexed as
Chinaconsensusconversion therapyHepatocellular carcinoma (HCC)locoregional treatmentsurgical resectionsystematic treatment
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.